NEWS BLOG

Cell therapy aims to introduce new, healthy cells into a patient’s body, to replace the diseased or missing ones.

Gene therapy has been studied for over 40 years and can help stop or slow the effects of disease at the most basic level - genes

Please attend our upcoming event, the Momentum in Cell and Gene Therapy Symposium which is co-organized by ART-TG (Inserm) and...

Great Ormond Street Hospital (GOSH), supported by LifeArc and Great Ormond Street Hospital Children’s Charity (GOSH Charity), has...

Outstanding Achievement Award Seppo Yla-Herttuala, University of Eastern Finland, Kuoppio Dr. Seppo Yla-Herttuala, MD, PhD, is a world leader in viral gene therapy for cardiovascular diseases and brain and bladder cancer. His team was the first to use adenovirus-mediated gene transfer to human arteries already in 1995. Since then, he has conducted 12 phase 1-3 clinical trials in cardiovascular and cancer gene therapy. He has also been heavily involved in angiogenesis research

Milano 29 January to 1 February See photos from this year's Academy below... ESGCT is committed to the training and support of students...

San Sebastián, Spain, December 14, 2023 - VIVEbiotech, S.L., a GMP contract development and manufacturing organization (CDMO) full...

The ESGCT, SFTCG and NVGCT Collaborative Congress took place from 24-27 October 2023 at Tour & Taxis, Brussels, Belgium. View Congress Programme View Clinical Trials and Commercialisation Workshop Programme View Poster List The Human Gene Therapy abstract publication is available at https://www.liebertpub.com/doi/10.1089/hum.2023.29258.abstracts . View Congress photos Statistics and Survey Results Sponsors and Partners We are very grateful for the support of all our partne

FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T...

The ESGCT would like to congratulate Katalin Karikó and Drew Weissman for their discoveries concerning nucleoside base modifications that...

6th Spring School, Giens, France 28 to 31 March, 2023 Programme

The MAGIC consortium is committed to making a meaningful impact on the lives of individuals affected by muscular dystrophies.

Annual meeting of the European Tissue Repair Society (ETRS) and Portuguese Society of Stem Cells and Cell Therapies (SPCE), October 2023.

The prestigious Johann Georg Zimmermann Medal was awarded this year to LIT scientist Prof. Dr. Hinrich Abken.

This award has been created to recognise individuals for their outstanding contribution to ESGCT and their commitment to Society’s...

OCTOBER 23, 2023 BRUSSELS, BELGIUM The Transatlantic Gene Therapy Consortium gladly invites you to join us at the 13th Stem Cell...

It is with great pleasure that the board of the ESGCT confers to professor Seppo Yla-Herttuala the award to his outstanding career....

The candidate will be involved in projects that aim to develop genome editing strategies for treatment of retinal and metabolic diseases.

Pfizer Global Medical Grants have opened a request for proposals that advance our understanding of Duchenne muscular dystrophy.

November 8-10, 2023, Rotterdam.